Peter Demuth - Net Worth and Insider Trading

Peter Demuth Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Peter Demuth owns 1 companies in total, including Elicio Therapeutics Inc (ELTX) .

Click here to see the complete history of Peter Demuth’s form 4 insider trades.

Insider Ownership Summary of Peter Demuth

Ticker	Comapny	Transaction Date	Type of Owner
ELTX	Elicio Therapeutics Inc	2023-06-01	Chief Scientific Officer

Peter Demuth Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Peter Demuth Ownership Network

Ownership Network List of Peter Demuth

No Data

Ownership Network Relation of Peter Demuth

Peter Demuth Owned Company Details

What does Elicio Therapeutics Inc do?

Who are the key executives at Elicio Therapeutics Inc?

Peter Demuth is the Chief Scientific Officer of Elicio Therapeutics Inc. Other key executives at Elicio Therapeutics Inc include Chief Financial Officer Brian Piekos , See Remarks Christopher Haqq , and director & CEO & President and Director Robert Connelly .

Elicio Therapeutics Inc (ELTX) Insider Trades Summary

Over the past 18 months, Peter Demuth made no insider transaction in Elicio Therapeutics Inc (ELTX). Other recent insider transactions involving Elicio Therapeutics Inc (ELTX) include a net purchase of 1,213,000 shares made by Yekaterina Chudnovsky ,

In summary, during the past 3 months, insiders sold 0 shares of Elicio Therapeutics Inc (ELTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Elicio Therapeutics Inc (ELTX) were sold and 1,213,000 shares were bought by its insiders, resulting in a net purchase of 1,213,000 shares.

Elicio Therapeutics Inc (ELTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Elicio Therapeutics Inc Insider Transactions

No Available Data

Peter Demuth Mailing Address

Above is the net worth, insider trading, and ownership report for Peter Demuth. You might contact Peter Demuth via mailing address: C/o Elicio Therapeutics, Inc., 451 D Street, 5th Floor, Suite 501, Boston Ma 02210.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.